Open clinical trial of rifabutin and clarithromycin therapy in Crohn’s disease

Digestive and Liver Disease

Volumn 34, Issue 1, 2002, Pages 22-28

  Shafran, I ^a   Kugler, L ^a   El Zaatari, F A K ^b   Naser, S A ^a   Sandoval, J ^a  

^a UNIVERSITY OF CENTRAL FLORIDA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anti mycobacterial antibiotics; Crohn's; Macrolide antibiotics; Mycobacterium avium subsp. Paratuberculosis

Indexed keywords

ANTIINFLAMMATORY AGENT; BACTERIAL PROTEIN; CLARITHROMYCIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; LIVER ENZYME; MACROLIDE; MESALAZINE; PROBIOTIC AGENT; PROTEIN P35; RECOMBINANT PROTEIN; RIFABUTIN;

ADULT; AGED; APPETITE DISORDER; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DRUG TOLERABILITY; ENTERITIS; FATIGUE; FEMALE; HEADACHE; HERXHEIMER REACTION; HUMAN; INSOMNIA; IRITIS; LEUKOPENIA; MALE; MYCOBACTERIUM PARATUBERCULOSIS; MYCOSIS; NAUSEA; PATIENT MONITORING; PRURITUS; SCORING SYSTEM; SEROLOGY; SKIN MANIFESTATION; SUBSPECIES; TOOTH DISEASE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; CLARITHROMYCIN; COLONOSCOPY; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM PARATUBERCULOSIS; PARATUBERCULOSIS; REMISSION INDUCTION; RIFABUTIN; TREATMENT OUTCOME;

EID: 0036190153     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(02)80055-X     Document Type: Article

References (31)

1. Chronic intestinal enteritis
2. Medical therapy of active Crohn's disease
3. Current concepts in pathogenesis of Crohn's disease
4. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease
5. Characteristics of an unclassified mycobacterium species isolated from patients with Crohn's disease
6. Crohn's disease isolated mycobacteria are identical to MAP as determined by DNA probes that distinguish mycobacterial species
7. MAP DNA in Crohn's disease tissue
8. PCR detection of Mycobacterium Paratuberculosis in long-term cultures from Crohn's disease tissues
9. MAP in Crohn's disease is serologically positive
10. Screening of a MAP expression library with polyclonal antiserum and amplified DNA probes to identify species-specific immunodominant antigens
11. Use of short-term culture for the identification of Mycobacterium avium subs. Paratuberculosis in tissue from Crohn's disease patients
12. Isolation of MAP from breast milk of Crohn's disease patients
13. Antimycobacterial therapy in Crohn's disease: Results of a controlled, double blind trial with a multiple antibiotic regimen
14. Metronidazole therapy for Crohn's disease and associated fistulae
15. Activity of clarithromycin against intracellular MAP-putative agent of Crohn's disease
16. Effects of Clarithromycin and Rifabutin alone and in combination on intracellular and extra-cellular replication of Mycobacterium avium
17. Two-year-outcomes analysis of Crohn's disease treated with Rifabutin and macrolide antibiotics
18. Antimycobacterial therapy ineffective in Crohn's disease after a year
19. Treatment of severe Crohn's disease (CD) using rifabutin-macrolide-clofazimine combination; iterim report
20. Use of antibiotics in the treatment of active Crohn's disease: Experience with metronidazole and ciprofloxacin
21. Prolonged remission in Crohn's disease following therapy for M. Para infection
22. Mycobacterial aetiology of Crohn's disease: Serologic study using common Mycobacterial antigens and a species-specific glycolipid antigen from MAP
23. Antimicrobial agents and Crohn's disease: Do they have a therapeutic role?
24. Antibodies to MAP and nine species of environmental Mycobacteria in Crohn's disease and control subjects
25. Immunoglobulin A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease
26. Identification and characterization of M. paratuberculosis recombinant clones expressed in E. coli
27. Characterization and seroreactivity of a specific MAP recombinant clone expressing 35K antigen with clinical and subclinical Johne's disease
28. Characterization of MAP p36 antigen and its seroreactivities in Crohn's Disease
29. Development of a Crohn's disease activity index
30. Clinical pathology of the Jarisch-Herxheimer reaction
31. Louse borne relapsing fever (LBRF) mortality and frequency of Jarisch-Herxheimer reaction